NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Clinical trials for NON-MUSCLE INVASIVE BLADDER NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NON-MUSCLE INVASIVE BLADDER NEOPLASMS trials appear
Sign up with your email to follow new studies for NON-MUSCLE INVASIVE BLADDER NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New bladder cancer treatment TAR-200 tested in Real-World study
Disease control Recruiting nowThis study follows 150 people with early-stage bladder cancer (NMIBC) who are receiving TAR-200 treatment in everyday medical practice. Researchers want to see how long it takes for the cancer to come back or get worse after starting TAR-200. The goal is to understand how well th…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
New shot for bladder tumors shows promise in early trial
Disease control Recruiting nowThis early-stage study is testing a new drug, belzupacap sarotalocan, injected directly into bladder tumors to see if it's safe and doable for people with non-muscle-invasive bladder cancer. About 55 participants will receive the injection, sometimes with a laser, and be monitore…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE1 • Sponsor: Aura Biosciences • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
New combo therapy aims to keep bladder cancer from coming back
Disease control Recruiting nowThis study tests whether adding the experimental drug V940 to standard BCG immunotherapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning or spreading. About 308 adults whose bladder cancer has not invaded the muscle will b…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
New targeted drug aims to keep bladder cancer from coming back
Disease control Recruiting nowThis study tests a new treatment called TAR-210 for people with a high-risk type of bladder cancer that has a specific genetic change (FGFR alteration). Participants have already received standard BCG therapy. The study compares TAR-210 to standard chemotherapy placed directly in…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New targeted therapy aims to keep bladder cancer from coming back
Disease control Recruiting nowThis study compares a new drug delivery system (TAR-210) to standard chemotherapy for people with a specific type of bladder cancer that hasn't invaded muscle. The treatment is placed directly into the bladder. About 641 participants will be randomly assigned to receive either TA…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
Bladder cancer drug delivered straight to the source shows promise in early trial
Disease control Recruiting nowThis study tests a new way to deliver the drug erdafitinib directly into the bladder using a special system called TAR-210. It is for people with bladder cancer that has not spread into the muscle layer or has spread into it. The goal is to find the best dose and see if it is saf…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC